Against this backdrop, nanodrugs promote the release of tumor antigens and DAMPs, allowing antigen-presenting cells to capture and present them to CD8+ T cells, leading to the activation of CD8+ T cells and enhancing their specific cytotoxic effects against cancer cells. This evidence concerns the gene CD8A and cancer.